Growth & profitability
- Revenue has grown 34.9% per year over the past 5 years.
RLYB Financials Rallybio Corp
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $858000 | -$9M | 0.0% | -3853.6% | — | — | $31M |
| 2024 | $636000 | -$58M | 0.0% | -9511.9% | -$49M | — | $14M |
| 2023 | — | -$75M | — | — | -$60M | — | $24M |
| 2022 | — | -$67M | — | — | -$57M | — | $57M |
| 2021 | — | -$47M | — | — | -$46M | — | $175M |
| 2020 | — | -$26M | — | — | -$22M | — | $140M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $212000 | -$8M | 0.0% | -4119.3% | — | — | $41M |
| Dec '25 | $222000 | -$6M | 0.0% | -2888.3% | — | — | $31M |
| Sep '25 | $212000 | $16M | 0.0% | -3266.5% | — | — | $32M |
| Jun '25 | $212000 | -$10M | 0.0% | -4743.9% | — | — | $9M |
| Mar '25 | $212000 | -$9M | 0.0% | -4561.3% | — | — | $15M |
| Dec '24 | $38000 | -$11M | 0.0% | -30547.4% | — | — | $14M |
| Sep '24 | $299000 | -$11M | 0.0% | -4035.5% | — | — | $25M |
| Jun '24 | $299000 | -$16M | 0.0% | -5697.3% | — | — | $17M |
| Mar '24 | $0 | -$19M | — | — | — | — | $19M |
| Dec '23 | — | -$20M | — | — | -$12M | — | $24M |
| Sep '23 | $0 | -$18M | — | — | -$16M | — | $19M |
| Jun '23 | $0 | -$19M | — | — | -$13M | — | $33M |
| Mar '23 | — | -$17M | — | — | -$19M | — | $40M |
| Dec '22 | — | -$16M | — | — | -$15M | — | $57M |
| Sep '22 | — | -$18M | — | — | -$15M | — | $52M |
| Jun '22 | — | -$18M | — | — | -$14M | — | $61M |
| Mar '22 | — | -$14M | — | — | -$14M | — | $81M |
| Dec '21 | — | -$12M | — | — | -$10M | — | $175M |
| Sep '21 | — | -$10M | — | — | -$11M | — | $187M |
| Jun '21 | — | -$11M | — | — | -$13M | — | $113M |
Valuation over time
How the market has priced RLYB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 8.2× (Dec '24) to 97.1× (Jun '26).
P/S
Frequently asked questions
Is RLYB growing its revenue and profit?
Over the past 5 years, Rallybio Corp's revenue has grown 34.9% per year. These are computed facts, not advice.
How much debt does RLYB have?
As of FY2025, Rallybio Corp reported — of total debt against $31M of cash.
What is RLYB's profit margin?
In FY2025, gross margin was —, operating margin -3853.6%, and net margin -1046.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.